FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200107294> ?p ?o ?g. }

• W4200107294 endingPage "1095" @default.
• W4200107294 startingPage "1081" @default.
• W4200107294 abstract "There are currently no approved treatments solely for unclassifiable interstitial lung disease (uILD); however, a recent trial showed this population can benefit from pirfenidone. We report a subgroup analysis of this trial to assess the effects of immunomodulators (concomitant mycophenolate mofetil [MMF] and/or previous corticosteroids) with pirfenidone in patients with uILD. This was a multicenter, international, double-blind, randomized, placebo-controlled phase II trial of patients with progressive fibrosing uILD (NCT03099187). Patients were randomized (1:1) to receive pirfenidone 2403 mg/day or placebo. This analysis assessed forced vital capacity (FVC) change from baseline measured using site spirometry (key secondary endpoint) and safety over 24 weeks by concomitant MMF use at randomization (pre-specified analysis) and/or previous corticosteroid use (post hoc analysis). Overall, 253 patients were randomized, including 45 (17.8%) patients (pirfenidone, n = 23; placebo, n = 22) receiving concomitant MMF with/without previous corticosteroids (MMF subgroup); 79 (31.2%) patients (pirfenidone, n = 44; placebo, n = 35) receiving previous corticosteroids without MMF (corticosteroids/no-MMF subgroup); and 129 (51.0%) patients (pirfenidone, n = 60; placebo, n = 69) not receiving concomitant MMF or previous corticosteroids (no-corticosteroids/no-MMF subgroup). At 24 weeks, difference in mean (95% confidence interval) FVC change from baseline between pirfenidone and placebo was − 55.4 mL (− 206.7, 96.0; P = 0.4645) in the MMF subgroup; 128.4 mL (− 6.4, 263.3; P = 0.0617) in the corticosteroids/no-MMF subgroup; and 115.5 mL (35.1, 195.9; P = 0.0052) in the no-corticosteroids/no-MMF subgroup. All subgroups generally exhibited a similar pattern of treatment-emergent adverse events. Although limited by design and small sample sizes, this analysis suggests pirfenidone may be less effective in patients with uILD receiving concomitant MMF, whereas a beneficial treatment effect was observed in patients not receiving concomitant MMF regardless of previous corticosteroid use. Pirfenidone was well tolerated regardless of MMF and/or corticosteroid use. ClinicalTrials.gov: NCT03099187." @default.
• W4200107294 created "2021-12-31" @default.
• W4200107294 creator A5006969715 @default.
• W4200107294 creator A5014703126 @default.
• W4200107294 creator A5019246724 @default.
• W4200107294 creator A5028036860 @default.
• W4200107294 creator A5031034216 @default.
• W4200107294 creator A5045956987 @default.
• W4200107294 creator A5046825438 @default.
• W4200107294 creator A5058325633 @default.
• W4200107294 date "2021-12-22" @default.
• W4200107294 modified "2023-10-18" @default.
• W4200107294 title "Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use" @default.
• W4200107294 cites W1665076041 @default.
• W4200107294 cites W1857071204 @default.
• W4200107294 cites W1857313506 @default.
• W4200107294 cites W2010503456 @default.
• W4200107294 cites W2098305693 @default.
• W4200107294 cites W2131014787 @default.
• W4200107294 cites W2138871107 @default.
• W4200107294 cites W2168666423 @default.
• W4200107294 cites W2472891063 @default.
• W4200107294 cites W2498506084 @default.
• W4200107294 cites W2513275059 @default.
• W4200107294 cites W2558303123 @default.
• W4200107294 cites W2794157908 @default.
• W4200107294 cites W2804608419 @default.
• W4200107294 cites W2890146673 @default.
• W4200107294 cites W2899088846 @default.
• W4200107294 cites W2906077632 @default.
• W4200107294 cites W2945521814 @default.
• W4200107294 cites W2964216559 @default.
• W4200107294 cites W2974960379 @default.
• W4200107294 cites W2975597462 @default.
• W4200107294 cites W3137016834 @default.
• W4200107294 cites W3145332293 @default.
• W4200107294 doi "https://doi.org/10.1007/s12325-021-02009-w" @default.
• W4200107294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34936057" @default.
• W4200107294 hasPublicationYear "2021" @default.
• W4200107294 type Work @default.
• W4200107294 citedByCount "4" @default.
• W4200107294 countsByYear W42001072942022 @default.
• W4200107294 countsByYear W42001072942023 @default.
• W4200107294 crossrefType "journal-article" @default.
• W4200107294 hasAuthorship W4200107294A5006969715 @default.
• W4200107294 hasAuthorship W4200107294A5014703126 @default.
• W4200107294 hasAuthorship W4200107294A5019246724 @default.
• W4200107294 hasAuthorship W4200107294A5028036860 @default.
• W4200107294 hasAuthorship W4200107294A5031034216 @default.
• W4200107294 hasAuthorship W4200107294A5045956987 @default.
• W4200107294 hasAuthorship W4200107294A5046825438 @default.
• W4200107294 hasAuthorship W4200107294A5058325633 @default.
• W4200107294 hasBestOaLocation W42001072941 @default.
• W4200107294 hasConcept C126322002 @default.
• W4200107294 hasConcept C141071460 @default.
• W4200107294 hasConcept C142724271 @default.
• W4200107294 hasConcept C168563851 @default.
• W4200107294 hasConcept C187960798 @default.
• W4200107294 hasConcept C203092338 @default.
• W4200107294 hasConcept C204243189 @default.
• W4200107294 hasConcept C204787440 @default.
• W4200107294 hasConcept C27081682 @default.
• W4200107294 hasConcept C2777543607 @default.
• W4200107294 hasConcept C2777714996 @default.
• W4200107294 hasConcept C2778341716 @default.
• W4200107294 hasConcept C2779384505 @default.
• W4200107294 hasConcept C2779832356 @default.
• W4200107294 hasConcept C44249647 @default.
• W4200107294 hasConcept C71924100 @default.
• W4200107294 hasConcept C90924648 @default.
• W4200107294 hasConceptScore W4200107294C126322002 @default.
• W4200107294 hasConceptScore W4200107294C141071460 @default.
• W4200107294 hasConceptScore W4200107294C142724271 @default.
• W4200107294 hasConceptScore W4200107294C168563851 @default.
• W4200107294 hasConceptScore W4200107294C187960798 @default.
• W4200107294 hasConceptScore W4200107294C203092338 @default.
• W4200107294 hasConceptScore W4200107294C204243189 @default.
• W4200107294 hasConceptScore W4200107294C204787440 @default.
• W4200107294 hasConceptScore W4200107294C27081682 @default.
• W4200107294 hasConceptScore W4200107294C2777543607 @default.
• W4200107294 hasConceptScore W4200107294C2777714996 @default.
• W4200107294 hasConceptScore W4200107294C2778341716 @default.
• W4200107294 hasConceptScore W4200107294C2779384505 @default.
• W4200107294 hasConceptScore W4200107294C2779832356 @default.
• W4200107294 hasConceptScore W4200107294C44249647 @default.
• W4200107294 hasConceptScore W4200107294C71924100 @default.
• W4200107294 hasConceptScore W4200107294C90924648 @default.
• W4200107294 hasIssue "2" @default.
• W4200107294 hasLocation W42001072941 @default.
• W4200107294 hasLocation W42001072942 @default.
• W4200107294 hasLocation W42001072943 @default.
• W4200107294 hasLocation W42001072944 @default.
• W4200107294 hasLocation W42001072945 @default.
• W4200107294 hasLocation W42001072946 @default.
• W4200107294 hasOpenAccess W4200107294 @default.
• W4200107294 hasPrimaryLocation W42001072941 @default.
• W4200107294 hasRelatedWork W2070191099 @default.
• W4200107294 hasRelatedWork W2144927394 @default.

• next